Welcome to our dedicated page for Longeveron news (Ticker: $LGVNR), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Longeveron's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Longeveron's position in the market.
Rhea-AI Summary
Longeveron Inc. (LGVN) announces a 1-for-10 reverse stock split to increase per-share trading price and regain Nasdaq compliance. The split will convert every ten shares into one, reducing outstanding shares significantly.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.97%
Tags
-
Rhea-AI Summary
Longeveron Inc. announces 2024 strategic priorities focusing on advancing Lomecel-B™ in HLHS and Alzheimer’s disease. The company presented long-term survival data from ELPIS I trial at the American Heart Association, with additional clinical data from CLEAR MIND Phase 2a trial in Alzheimer’s disease. Financially, revenues decreased by 42% in 2023, with a gross profit decrease of 56%. General and administrative expenses increased by 40%, while research and development expenses decreased by 3%. Net loss increased by 14% in 2023. The company discontinued its Aging-related Frailty clinical trial in Japan to focus on HLHS and Alzheimer’s disease programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.99%
Tags
-
Rhea-AI Summary
Longeveron Inc. (LGVN) will report its 2023 financial results on February 27, 2024, followed by a conference call to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
Rhea-AI Summary
Longeveron Inc. announces receipt of a notice of patent allowance from the United States Patent and Trademark Office for Medicinal Signaling Cells (MSCs), the technology behind its lead investigational product Lomecel-BTM. The new patent impacts patients with Aging-related Frailty receiving vaccines for conditions such as Covid and the flu, adding to the company's growing patent estate. Longeveron is conducting a trial of Aging-related Frailty in Japan and recently announced positive results from its Phase 2 Alzheimer’s disease trial. The patent covers the impact of Lomecel-BTM on favorable modulation of the immune system, which is foundational in all of Longeveron’s indications under development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.13%
Tags
-
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announced the closing of a registered direct offering, raising approximately $2.36 million for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) has announced a registered direct offering priced at-the-market under Nasdaq rules, with the issuance and sale of 1,355,301 shares of common stock at $1.62 per share, as well as unregistered warrants to purchase up to 1,355,301 shares of common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.84%
Tags
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announces new clinical data showing Lomecel-B™ improved cognitive function and quality of life in Alzheimer's patients, with MRI biomarker study data confirming therapeutic potential in the treatment of mild Alzheimer's disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.92%
Tags
-
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) announced that extended long-term follow-up data from the ELPIS I trial of Lomecel-BTM for patients with hypoplastic left heart syndrome (HLHS) is being presented at the annual Scientific Sessions of the American Heart Association. The results show 100% survival and transplant-free status of all 10 patients for up to 5 years after receiving Lomecel-BTM during their Stage II surgery, supporting the ongoing ELPIS II trial. Lomecel-BTM has received Rare Pediatric Disease Designation, Fast Track Designation, and Orphan Drug Designation by the US FDA for the HLHS indication.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) announced positive top-line results from the CLEAR MIND clinical trial of Lomecel-B™ in treating mild Alzheimer’s disease, highlighting safety and efficacy signals. The company also secured $4 million in equity financing and reported long-term survival data from the ELPIS 1 trial to be presented at the 2023 Scientific Sessions of the American Heart Association. The company's financial results for the quarter ended September 30, 2023, show a net loss of approximately $5.1 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
News
Rhea-AI Summary
Longeveron Inc. (NASDAQ: LGVN) will report its third quarter 2023 financial results on November 10, 2023. The company will host a conference call and webcast to discuss the results and provide updates on its clinical programs and corporate activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
Longeveron Inc.
Nasdaq:LGVNR
LGVNR Rankings
LGVNR Stock Data
About LGVNR
longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome